4D Molecular Therapeutics Inc

FDMT

Healthcare|Biotechnology|USA

$12.30

-0.58 (-4.50%)

Tangible Book

$8.64

Clinical Trials (10)

Trial	Conditions	Phase	Status	Enrollment	Design	Drug
NCT06864988 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration	Macular Neovascularization Secondary to Age-Related Macular Degeneration	P3	Active	480	RCT, Double-blind	4D-150 IVT (3E10 vg/eye), EYLEA® (aflibercept) Injection 2 mg (0.05mL)
NCT07064759 Single Intravitreal (IVT) Injection of 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration	Neovascular Age-Related Macular Degeneration (nAMD)	P3	Recruiting	480	RCT, Double-blind	4D-150 IVT (3E10 vg/eye), EYLEA® (aflibercept) Injection 2 mg (0.05mL)
NCT05930561 4D-150 in Patients With Diabetic Macular Edema	Diabetic Macular Edema, Diabetic Retinopathy	P2	Active	72	Double-blind	4D-150 IVT, Aflibercept IVT
NCT05629559 4D-310 in Adults With Fabry Disease and Cardiac Involvement	Fabry Disease	P1P2	Recruiting	18	Open-label	4D-310
NCT04519749 An Open-label, Phase 1/2 Trial of Gene Therapy 4D-310 in Adults With Fabry Disease	Fabry Disease	P1P2	Active	18	Open-label	4D-310
NCT05248230 4D-710 in Adult Patients With Cystic Fibrosis	Cystic Fibrosis Lung	P2	Recruiting	30	Open-label	4D-710
NCT04517149 4D-125 in Patients With X-Linked Retinitis Pigmentosa (XLRP)	X-Linked Retinitis Pigmentosa	P1P2	Active	21	Open-label	4D-125 IVT Injection
NCT05197270 4D-150 in Patients With Neovascular (Wet) Age-Related Macular Degeneration	Neovascular (Wet) Age-Related Macular Degeneration	P1P2	Recruiting	215	RCT, Single-blind	4D-150 IVT, Aflibercept IVT
NCT04483440 Dose Escalation Study of Intravitreal 4D-110 in Patients With Choroideremia	Choroideremia	P1	Active	13	Open-label	4D-110
NCT02994368 "Natural History" Study of Choroideremia	Choroideremia		Terminated	57	—	—